<?xml version="1.0" encoding="UTF-8"?><!-- This information is licensed under the Queen's Printer License of British Columbia found: www.bclaws.ca/standards/2014/QP-License_1.0.html. Please review the license terms carefully. --><reg:regulation xmlns:reg="http://www.gov.bc.ca/2013/legislation/regulation" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bcl="http://www.gov.bc.ca/2013/bclegislation" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:in="http://www.qp.gov.bc.ca/2013/inline" xmlns:fun="http://www.bclaws.ca/xslt/functions" xmlns:act="http://www.gov.bc.ca/2013/legislation/act" xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table" xsi:schemaLocation="http://www.gov.bc.ca/2013/legislation/regulation  http://standards.qp.gov.bc.ca/standards/2013/regulation_1.0.xsd" id="344_2012">
  <reg:amend added="2013-06-24" effective="2013-03-01" regnum="344/2012"/>
  <reg:amend added="2013-09-23" effective="2013-04-01" regnum="159/2013" bullId="2013bull12"/>
  <reg:amend added="2014-03-20" effective="2014-03-01" regnum="344/2012" bullId="2012bull45"/>
  <reg:amend added="2014-05-01" effective="2014-04-01" regnum="344/2012" bullId="2012bull45"/>
  <reg:amend added="2016-05-03" effective="2016-01-01" regnum="255/2015" bullId="2015bull43"/>
  <reg:amend added="2016-05-17" effective="2016-01-29" regnum="10/2016" bullId="2016bull02"/>
  <reg:amend effective="2017-04-01" regnum="266/2016" bullId="2016bull39" hasGreenSheet="no" added="2017-05-08"/>
  <reg:amend effective="2019-04-01" regnum="22/2019" bullId="2019bull05" hasGreenSheet="no" added="2019-04-02"/>
  <reg:regnum>344/2012</reg:regnum>
  <reg:oic>O.C. 783/2012</reg:oic>
  <reg:deposited>November 23, 2012</reg:deposited>
  <reg:effective>sections 1 to 3, 6, 7 and 17 March 1, 2013<in:br/> remainder effective April 1, 2013</reg:effective>
  <reg:acttitle>Pharmaceutical Services Act</reg:acttitle>
  <reg:title>Drug Price Regulation</reg:title>
  <reg:amsincluded>[includes amendments up to B.C. Reg. 22/2019, April 1, 2019]</reg:amsincluded>
  <reg:regpitid>344_2012_pit</reg:regpitid>
  <reg:content>
    <bcl:part id="d2e40">
      <bcl:num>1</bcl:num>
      <bcl:text>Definitions and Application</bcl:text>
      <bcl:section id="d2e49">
        <bcl:marginalnote>Definitions</bcl:marginalnote>
        <bcl:num>1</bcl:num>
        <bcl:subsection id="d2e57">
          <bcl:num>1</bcl:num>
          <bcl:text>In this regulation:</bcl:text>
          <bcl:definition id="d2e66">
            <bcl:text>
              <in:term>Act</in:term> means the <bcl:link resource="leg" xlink:href="/legislation/12022_01" xlink:type="locator"><in:doc>Pharmaceutical Services Act</in:doc></bcl:link>;</bcl:text>
          </bcl:definition>
          <bcl:definition id="d2e78">
            <bcl:text>
              <in:term>brand drug</in:term> means a drug</bcl:text>
            <bcl:paragraph id="d2e88">
              <bcl:num>a</bcl:num>
              <bcl:text>for which the first notice of compliance has been issued under section C.08.004 or C.08.004.01 of the Food and Drug Regulations (Canada), C.R.C., c. 870, in respect of all 3 of the following:</bcl:text>
              <bcl:subparagraph id="d2e97">
                <bcl:num>i</bcl:num>
                <bcl:text>a particular active ingredient or combination of particular active ingredients;</bcl:text>
              </bcl:subparagraph>
              <bcl:subparagraph id="d2e106">
                <bcl:num>ii</bcl:num>
                <bcl:text>strength;</bcl:text>
              </bcl:subparagraph>
              <bcl:subparagraph id="d2e115">
                <bcl:num>iii</bcl:num>
                <bcl:text>dosage form, and</bcl:text>
              </bcl:subparagraph>
            </bcl:paragraph>
            <bcl:paragraph id="d2e124">
              <bcl:num>b</bcl:num>
              <bcl:text>that, before the issuance of any subsequent notice of compliance for another drug having the same active ingredient or combination of active ingredients, is or was marketed in Canada by</bcl:text>
              <bcl:subparagraph id="d2e133">
                <bcl:num>i</bcl:num>
                <bcl:text>the drug's innovator, or</bcl:text>
              </bcl:subparagraph>
              <bcl:subparagraph id="d2e143">
                <bcl:num>ii</bcl:num>
                <bcl:text>a person acting under a licence granted by the drug's innovator;</bcl:text>
              </bcl:subparagraph>
            </bcl:paragraph>
          </bcl:definition>
          <bcl:definition id="d2e152">
            <bcl:text>
              <in:term>generic drug</in:term> means a drug having the same active ingredient or combination of active ingredients as a brand drug;</bcl:text>
          </bcl:definition>
          <bcl:definition id="d1e169">
            <bcl:text>
              <in:term>generic drug inclusion or exclusion</in:term> means the inclusion of at least one additional generic drug in, or the exclusion of at least one generic drug from, an LCA category;</bcl:text>
          </bcl:definition>
          <bcl:definition id="d2e161">
            <bcl:text>
              <in:term>high cost drug</in:term> means a high cost drug designated under section 7 (1) <in:desc>[high cost drugs]</in:desc>;</bcl:text>
          </bcl:definition>
          <bcl:definition id="d2e173">
            <bcl:text>
              <in:term>LCA category</in:term> means a category of drugs established under section 3 (1) (a) <in:desc>[LCA program]</in:desc>;</bcl:text>
          </bcl:definition>
          <bcl:definition id="d2e185">
            <bcl:text>
              <in:term>LCA drug comparator</in:term> means the drug designated under section 3 (1) (c) as the LCA drug comparator for an LCA category;</bcl:text>
          </bcl:definition>
          <bcl:definition id="d2e194">
            <bcl:text>
              <in:term>LCA program</in:term> means the low cost alternative program under section 3;</bcl:text>
          </bcl:definition>
          <bcl:definition id="d2e204">
            <bcl:text>
              <in:term>manufacturer's list price</in:term> means the following:</bcl:text>
            <bcl:paragraph id="d1e239">
              <bcl:num>a</bcl:num>
              <bcl:text>in the case of an LCA category having an LCA drug comparator adopted from another jurisdiction under section 3.01 (1) (a) <in:desc>[LCA drug comparators may be adopted from other jurisdictions]</in:desc>, the manufacturer's list price per unit of the adopted drug in that jurisdiction;</bcl:text>
            </bcl:paragraph>
            <bcl:paragraph id="d1e251">
              <bcl:num>b</bcl:num>
              <bcl:text>in any other case, the price per unit of a drug, as provided by a manufacturer to the minister in the manner and at the time required by the minister;</bcl:text>
            </bcl:paragraph>
          </bcl:definition>
          <bcl:definition id="d2e213">
            <bcl:text>
              <in:term>maximum accepted list price</in:term> means the maximum accepted list price as determined by the minister under section 3 (3);</bcl:text>
          </bcl:definition>
          <bcl:definition id="d2e222">
            <bcl:text>
              <in:term>non-reference drug</in:term> means a drug, within a reference drug category, that has not been designated as a reference drug;</bcl:text>
          </bcl:definition>
          <bcl:definition id="d2e231">
            <bcl:text>
              <in:term>oral solid</in:term> means a drug that</bcl:text>
            <bcl:paragraph id="d2e240">
              <bcl:num>a</bcl:num>
              <bcl:text>is available in a solid form, including as a gel capsule, chewable tablet or wafer, and</bcl:text>
            </bcl:paragraph>
            <bcl:paragraph id="d2e249">
              <bcl:num>b</bcl:num>
              <bcl:text>is intended to be taken orally;</bcl:text>
            </bcl:paragraph>
          </bcl:definition>
          <bcl:definition id="d2e259">
            <bcl:text>
              <in:term>provisional drug</in:term> means a drug designated under section 14 (1) <in:desc>[designation of provisional drugs]</in:desc> as a provisional drug;</bcl:text>
          </bcl:definition>
          <bcl:definition id="d2e271">
            <bcl:text>
              <in:term>reference drug</in:term> means a drug, within a reference drug category, designated under section 6 (2) (b) <in:desc>[reference drug program]</in:desc> as a reference drug;</bcl:text>
          </bcl:definition>
          <bcl:definition id="d2e283">
            <bcl:text>
              <in:term>reference drug category</in:term> means a category of drugs listed in section 6 (1);</bcl:text>
          </bcl:definition>
          <bcl:definition id="d2e292">
            <bcl:text>
              <in:term>reference drug comparator</in:term> means the drug designated under section 6 (2) (c) as the reference drug comparator for a reference drug category.</bcl:text>
          </bcl:definition>
        </bcl:subsection>
        <bcl:subsection id="d2e301">
          <bcl:num>2</bcl:num>
          <bcl:text>Despite subsection (1), the minister may do one or both of the following for the purposes of the LCA program:</bcl:text>
          <bcl:paragraph id="d2e310">
            <bcl:num>a</bcl:num>
            <bcl:text>deem a generic drug to be a brand drug;</bcl:text>
          </bcl:paragraph>
          <bcl:paragraph id="d2e320">
            <bcl:num>b</bcl:num>
            <bcl:text>deem a brand drug to be a generic drug.</bcl:text>
          </bcl:paragraph>
        </bcl:subsection>
        <bcl:hnote>[am. B.C. Regs. 266/2016, Sch. 2, s. 1; 22/2019, s. 1.]</bcl:hnote>
      </bcl:section>
      <bcl:section id="d2e330">
        <bcl:marginalnote>Application</bcl:marginalnote>
        <bcl:num>2</bcl:num>
        <bcl:text>This regulation applies only to drugs, except insulin, that are benefits under the Act.</bcl:text>
      </bcl:section>
    </bcl:part>
    <bcl:part id="d2e342">
      <bcl:num>2</bcl:num>
      <bcl:text>Maximum Amounts Payable by Minister</bcl:text>
      <bcl:division id="d2e351">
        <bcl:num>1</bcl:num>
        <bcl:text>Drug Programs</bcl:text>
        <bcl:section id="d2e364">
          <bcl:marginalnote>Low cost alternative program</bcl:marginalnote>
          <bcl:num>3</bcl:num>
          <bcl:subsection id="d2e372">
            <bcl:num>1</bcl:num>
            <bcl:text>For the purposes of the low cost alternative program, the minister</bcl:text>
            <bcl:paragraph id="d2e381">
              <bcl:num>a</bcl:num>
              <bcl:text>may establish LCA categories consisting of drugs that have the same active ingredient or combination of active ingredients, and the same strength,</bcl:text>
            </bcl:paragraph>
            <bcl:paragraph id="d2e390">
              <bcl:num>b</bcl:num>
              <bcl:text>may, for each category, determine which drugs are included, and</bcl:text>
            </bcl:paragraph>
            <bcl:paragraph id="d2e400">
              <bcl:num>c</bcl:num>
              <bcl:text>may, for each category established on or after April 1, 2013, designate one drug as the LCA drug comparator.</bcl:text>
            </bcl:paragraph>
          </bcl:subsection>
          <bcl:subsection id="d2e409">
            <bcl:num>2</bcl:num>
            <bcl:text>If the minister designates an LCA drug comparator, the minister must designate the LCA drug comparator as follows:</bcl:text>
            <bcl:paragraph id="d2e418">
              <bcl:num>a</bcl:num>
              <bcl:text>if there is a single brand drug in an LCA category, that brand drug;</bcl:text>
            </bcl:paragraph>
            <bcl:paragraph id="d2e427">
              <bcl:num>b</bcl:num>
              <bcl:text>if there is more than one brand drug in an LCA category, the brand drug that, in the opinion of the minister is the most cost-effective of the brand drugs in the category;</bcl:text>
            </bcl:paragraph>
            <bcl:paragraph id="d2e436">
              <bcl:num>c</bcl:num>
              <bcl:text>if there are no brand drugs in an LCA category, the LCA drug comparator of another LCA category having drugs with the same active ingredient or combination of active ingredients, but a different strength, as the first LCA category;</bcl:text>
            </bcl:paragraph>
            <bcl:paragraph id="d1e509">
              <bcl:num>d</bcl:num>
              <bcl:text>despite paragraphs (a) to (c), if section 3.01 <in:desc>[LCA drug comparators may be adopted from other jurisdictions]</in:desc> applies, as described in that section.</bcl:text>
            </bcl:paragraph>
          </bcl:subsection>
          <bcl:subsection id="d2e445">
            <bcl:num>3</bcl:num>
            <bcl:text>The minister must determine the maximum accepted list price for the drugs in each LCA category in accordance with the following, as applicable:</bcl:text>
            <bcl:paragraph id="d2e455">
              <bcl:num>a</bcl:num>
              <bcl:text>section 4 <in:desc>[LCA categories established on or after April 1, 2013]</in:desc>;</bcl:text>
            </bcl:paragraph>
            <bcl:paragraph id="d2e467">
              <bcl:num>b</bcl:num>
              <bcl:text>section 5 <in:desc>[LCA categories established before April 1, 2013]</in:desc>.</bcl:text>
            </bcl:paragraph>
          </bcl:subsection>
          <bcl:subsection id="d2e479">
            <bcl:num>4</bcl:num>
            <bcl:text>The minister may change or cancel a determination or designation made under this section, including cancelling the establishment of an LCA category.</bcl:text>
          </bcl:subsection>
          <bcl:subsection id="d2e488">
            <bcl:num>5</bcl:num>
            <bcl:text>A change or cancellation under subsection (4) may be made at any time without notice to anyone or an opportunity to be heard.</bcl:text>
          </bcl:subsection>
          <bcl:subsection id="d2e497">
            <bcl:num>6</bcl:num>
            <bcl:text>The minister must publish on the website of the ministry of the minister all of the following:</bcl:text>
            <bcl:paragraph id="d2e506">
              <bcl:num>a</bcl:num>
              <bcl:text>a list of all LCA categories;</bcl:text>
            </bcl:paragraph>
            <bcl:paragraph id="d2e516">
              <bcl:num>b</bcl:num>
              <bcl:text>for each LCA category, the maximum amount the minister may pay under the Act for a drug within the LCA category.</bcl:text>
            </bcl:paragraph>
          </bcl:subsection>
          <bcl:hnote>[am. B.C. Reg. 22/2019, s. 2.]</bcl:hnote>
        </bcl:section>
        <bcl:section id="d1e614">
          <bcl:marginalnote>LCA drug comparators may be adopted from other jurisdictions</bcl:marginalnote>
          <bcl:num>3.01</bcl:num>
          <bcl:subsection id="d1e622">
            <bcl:num>1</bcl:num>
            <bcl:text>If, under subsection (2) of this section, this subsection applies to an LCA category established under section 3 (1) (a), the minister may designate an LCA drug comparator for the category as follows:</bcl:text>
            <bcl:paragraph id="d1e630">
              <bcl:num>a</bcl:num>
              <bcl:text>by adopting as the LCA drug comparator a brand drug that is used by another jurisdiction of Canada as the reference drug to determine prices for a category of drugs, established in that jurisdiction, that is similar to the LCA category;</bcl:text>
            </bcl:paragraph>
            <bcl:paragraph id="d1e639">
              <bcl:num>b</bcl:num>
              <bcl:text>if the brand drug referred to in paragraph (a) of this subsection is not on a formulary of British Columbia, or for any other reason, in accordance with section 3 (2) (a) to (c), as applicable.</bcl:text>
            </bcl:paragraph>
          </bcl:subsection>
          <bcl:subsection id="d1e649">
            <bcl:num>2</bcl:num>
            <bcl:text>Subsection (1) applies to an LCA category as follows:</bcl:text>
            <bcl:paragraph id="d1e657">
              <bcl:num>a</bcl:num>
              <bcl:text>if the LCA category is established before April 1, 2014 and has no generic drug inclusions or exclusions before April 1, 2019, subsection (1) applies as of the date of the first generic drug inclusion or exclusion that occurs on or after April 1, 2019;</bcl:text>
            </bcl:paragraph>
            <bcl:paragraph id="d1e666">
              <bcl:num>b</bcl:num>
              <bcl:text>if the LCA category is established</bcl:text>
              <bcl:subparagraph id="d1e674">
                <bcl:num>i</bcl:num>
                <bcl:text>before April 1, 2014 but has a generic drug inclusion or exclusion on or after April 1, 2014 but before April 1, 2019, or</bcl:text>
              </bcl:subparagraph>
              <bcl:subparagraph id="d1e683">
                <bcl:num>ii</bcl:num>
                <bcl:text>on or after April 1, 2014 but before April 1, 2019,</bcl:text>
              </bcl:subparagraph>
              <bcl:text>subsection (1) applies as of the date of the first generic drug inclusion or exclusion that occurs on or after April 1, 2019, and causes the LCA category to move into a different tier as described in subsection (3);</bcl:text>
            </bcl:paragraph>
            <bcl:paragraph id="d1e696">
              <bcl:num>c</bcl:num>
              <bcl:text>if the LCA category is established on or after April 1, 2019, subsection (1) applies as of the date that the LCA category is established.</bcl:text>
            </bcl:paragraph>
          </bcl:subsection>
          <bcl:subsection id="d1e706">
            <bcl:num>3</bcl:num>
            <bcl:text>For the purposes of subsection (2) (b), an LCA category moves into a different tier if any of the following occurs:</bcl:text>
            <bcl:paragraph id="d1e714">
              <bcl:num>a</bcl:num>
              <bcl:text>a category having only one generic drug has at least one more generic drug included in the category;</bcl:text>
            </bcl:paragraph>
            <bcl:paragraph id="d1e723">
              <bcl:num>b</bcl:num>
              <bcl:text>a category having only 2 generic drugs has</bcl:text>
              <bcl:subparagraph id="d1e731">
                <bcl:num>i</bcl:num>
                <bcl:text>one generic drug excluded from the category such that only one generic drug remains in that category, or</bcl:text>
              </bcl:subparagraph>
              <bcl:subparagraph id="d1e740">
                <bcl:num>ii</bcl:num>
                <bcl:text>at least one more generic drug included in the category;</bcl:text>
              </bcl:subparagraph>
            </bcl:paragraph>
            <bcl:paragraph id="d1e750">
              <bcl:num>c</bcl:num>
              <bcl:text>a category having 3 or more generic drugs has generic drugs excluded from the category such that only one or 2 generic drugs remain in that category.</bcl:text>
            </bcl:paragraph>
          </bcl:subsection>
          <bcl:hnote>[en. B.C. Reg. 22/2019, s. 3.]</bcl:hnote>
        </bcl:section>
        <bcl:section id="d0e579">
          <bcl:marginalnote>Repealed</bcl:marginalnote>
          <bcl:num>3.1</bcl:num>
          <bcl:text>Repealed. [B.C. Reg. 22/2019, s. 4.]</bcl:text>
        </bcl:section>
        <bcl:section id="d2e526">
          <bcl:marginalnote>Low cost alternative categories established on or after April 1, 2013</bcl:marginalnote>
          <bcl:num>4</bcl:num>
          <bcl:subsection id="d2e534">
            <bcl:num>1</bcl:num>
            <bcl:text>This section applies to LCA categories established on or after April 1, 2013.</bcl:text>
          </bcl:subsection>
          <bcl:subsection id="d2e543">
            <bcl:num>2</bcl:num>
            <bcl:text>Except as set out in subsections (3) and (4), the maximum accepted list price for drugs in an LCA category that meets both of the following criteria is 25% of the manufacturer's list price for the LCA drug comparator for the LCA category, as of the date on which a generic drug is first included in or excluded from the category after April 1, 2019:</bcl:text>
            <bcl:paragraph id="d2e552">
              <bcl:num>a</bcl:num>
              <bcl:text>the LCA category consists of drugs available as oral solids only;</bcl:text>
            </bcl:paragraph>
            <bcl:paragraph id="d2e562">
              <bcl:num>b</bcl:num>
              <bcl:text>the LCA category was established</bcl:text>
              <bcl:subparagraph id="d1e820">
                <bcl:num>i</bcl:num>
                <bcl:text>on or after April 1, 2019, or</bcl:text>
              </bcl:subparagraph>
              <bcl:subparagraph id="d1e829">
                <bcl:num>ii</bcl:num>
                <bcl:text>before April 1, 2019, but has a generic drug inclusion or exclusion on or after April 1, 2019.</bcl:text>
              </bcl:subparagraph>
            </bcl:paragraph>
          </bcl:subsection>
          <bcl:subsection id="d1e840">
            <bcl:num>2.1</bcl:num>
            <bcl:text>Except as set out in subsections (3) and (4), the maximum accepted list price for drugs in an LCA category is the following percentage of the manufacturer's list price for the LCA drug comparator for that LCA category, as of the date on which a generic drug is first assigned to that LCA category:</bcl:text>
            <bcl:paragraph id="d1e848">
              <bcl:num>a</bcl:num>
              <bcl:text>20%, if the LCA category consists of drugs available as oral solids only but subsection (2) does not apply;</bcl:text>
            </bcl:paragraph>
            <bcl:paragraph id="d1e857">
              <bcl:num>b</bcl:num>
              <bcl:text>35%, in any other case.</bcl:text>
            </bcl:paragraph>
          </bcl:subsection>
          <bcl:subsection id="d2e571">
            <bcl:num>3</bcl:num>
            <bcl:text>If the manufacturer's list price of an LCA drug comparator decreased by more than 20% within 2 years before a generic drug is first assigned to the LCA category, the date for the purposes of subsection (2) is the date that is 2 years before a generic drug is first assigned to that LCA category.</bcl:text>
          </bcl:subsection>
          <bcl:subsection id="d2e580">
            <bcl:num>4</bcl:num>
            <bcl:text>If section 3 (2) (c) <in:desc>[LCA program]</in:desc> applies, the maximum accepted list price for drugs in the LCA category having no brand drugs is proportional, depending on their strength, to the maximum accepted list price that applies to the LCA category to which the designated LCA drug comparator belongs.</bcl:text>
          </bcl:subsection>
          <bcl:hnote>[am. B.C. Regs. 344/2012, s. (d); 22/2019, s. 5.]</bcl:hnote>
        </bcl:section>
        <bcl:section id="d2e593">
          <bcl:marginalnote>Low cost alternative categories established before April 1, 2013</bcl:marginalnote>
          <bcl:num>5</bcl:num>
          <bcl:subsection id="d2e601">
            <bcl:num>1</bcl:num>
            <bcl:text>This section applies to LCA categories established before April 1, 2013.</bcl:text>
          </bcl:subsection>
          <bcl:subsection id="d2e610">
            <bcl:num>2</bcl:num>
            <bcl:text>Except as set out in subsection (3), the maximum accepted list price for drugs in an LCA category listed in Column 1 of the Schedule is as follows:</bcl:text>
            <bcl:paragraph id="d2e619">
              <bcl:num>a</bcl:num>
              <bcl:text>25% of the base price set out in Column 2 of the Schedule opposite the LCA category if the LCA category</bcl:text>
              <bcl:subparagraph id="d1e932">
                <bcl:num>i</bcl:num>
                <bcl:text>consists of drugs available as oral solids only, and</bcl:text>
              </bcl:subparagraph>
              <bcl:subparagraph id="d1e941">
                <bcl:num>ii</bcl:num>
                <bcl:text>has a generic drug inclusion or exclusion on or after April 1, 2019;</bcl:text>
              </bcl:subparagraph>
            </bcl:paragraph>
            <bcl:paragraph id="d2e629">
              <bcl:num>b</bcl:num>
              <bcl:text>20% of the base price set out in Column 2 of the Schedule opposite the LCA category if the LCA category consists of drugs available as oral solids only but paragraph (a) (ii) does not apply;</bcl:text>
            </bcl:paragraph>
            <bcl:paragraph id="d1e960">
              <bcl:num>c</bcl:num>
              <bcl:text>35% of the base price set out in Column 2 of the Schedule opposite that LCA category in any other case.</bcl:text>
            </bcl:paragraph>
          </bcl:subsection>
          <bcl:subsection id="d2e638">
            <bcl:num>3</bcl:num>
            <bcl:text>If a drug in an LCA category had, as of July 1, 2010, a lower manufacturer's list price than the maximum accepted list price calculated under subsection (2), the maximum accepted list price for drugs in the LCA category is the manufacturer's list price, as of July 1, 2010, of the lower priced drug.</bcl:text>
          </bcl:subsection>
          <bcl:subsection id="d2e647">
            <bcl:num>4</bcl:num>
            <bcl:text>The minister may deem, at any time, an LCA category established before April 1, 2013, to have been established on or after April 1, 2013, in which case,</bcl:text>
            <bcl:paragraph id="d2e656">
              <bcl:num>a</bcl:num>
              <bcl:text>the maximum accepted list price for drugs in the LCA category is to be determined in accordance with section 4 <in:desc>[LCA categories established on or after April 1, 2013]</in:desc>, and</bcl:text>
            </bcl:paragraph>
            <bcl:paragraph id="d2e668">
              <bcl:num>b</bcl:num>
              <bcl:text>for the purposes of section 4 (2.1), the date on which a generic drug is first assigned to the LCA category is deemed to be the date on which the minister deems the LCA category to have been established.</bcl:text>
            </bcl:paragraph>
          </bcl:subsection>
          <bcl:hnote>[am. B.C. Regs. 344/2012, s. (d); 22/2019, s. 6.]</bcl:hnote>
        </bcl:section>
        <bcl:section id="d2e678">
          <bcl:marginalnote>Reference drug program</bcl:marginalnote>
          <bcl:num>6</bcl:num>
          <bcl:subsection id="d2e686">
            <bcl:num>1</bcl:num>
            <bcl:text>The following are reference drug categories for the purposes of the reference drug program:</bcl:text>
            <bcl:paragraph id="d2e695">
              <bcl:num>a</bcl:num>
              <bcl:text>angiotensin converting enzyme inhibitors;</bcl:text>
            </bcl:paragraph>
            <bcl:paragraph id="d0e759">
              <bcl:num>b</bcl:num>
              <bcl:text>angiotensin receptor blockers;</bcl:text>
            </bcl:paragraph>
            <bcl:paragraph id="d2e704">
              <bcl:num>c</bcl:num>
              <bcl:text>dihydropyridine calcium channel blockers;</bcl:text>
            </bcl:paragraph>
            <bcl:paragraph id="d2e714">
              <bcl:num>d</bcl:num>
              <bcl:text>histamine-2 receptor antagonists;</bcl:text>
            </bcl:paragraph>
            <bcl:paragraph id="d0e786">
              <bcl:num>e</bcl:num>
              <bcl:text>hydroxyl-3-methylglutaryl-coenzyme A reductase inhibitors;</bcl:text>
            </bcl:paragraph>
            <bcl:paragraph id="d2e732">
              <bcl:num>f</bcl:num>
              <bcl:text>non-steroidal anti-inflammatory drugs;</bcl:text>
            </bcl:paragraph>
            <bcl:paragraph id="d2e723">
              <bcl:num>g</bcl:num>
              <bcl:text>oral nitrates;</bcl:text>
            </bcl:paragraph>
            <bcl:paragraph id="d0e813">
              <bcl:num>h</bcl:num>
              <bcl:text>proton pump inhibitors.</bcl:text>
            </bcl:paragraph>
          </bcl:subsection>
          <bcl:subsection id="d2e741">
            <bcl:num>2</bcl:num>
            <bcl:text>The minister may, for each category,</bcl:text>
            <bcl:paragraph id="d2e750">
              <bcl:num>a</bcl:num>
              <bcl:text>determine which drugs are included,</bcl:text>
            </bcl:paragraph>
            <bcl:paragraph id="d2e759">
              <bcl:num>b</bcl:num>
              <bcl:text>designate one or more drugs as reference drugs, and</bcl:text>
            </bcl:paragraph>
            <bcl:paragraph id="d2e769">
              <bcl:num>c</bcl:num>
              <bcl:text>designate one drug as the reference drug comparator.</bcl:text>
            </bcl:paragraph>
          </bcl:subsection>
          <bcl:subsection id="d2e778">
            <bcl:num>3</bcl:num>
            <bcl:text>A drug may be designated as a reference drug if the minister is of the opinion that the drug is at least as clinically efficacious or cost-effective as other drugs in the reference drug category.</bcl:text>
          </bcl:subsection>
          <bcl:subsection id="d2e787">
            <bcl:num>4</bcl:num>
            <bcl:text>The minister may designate any of the following as the reference drug comparator:</bcl:text>
            <bcl:paragraph id="d2e796">
              <bcl:num>a</bcl:num>
              <bcl:text>the reference drug that, in the opinion of the minister, is the most cost-effective of the reference drugs in the reference drug category;</bcl:text>
            </bcl:paragraph>
            <bcl:paragraph id="d2e805">
              <bcl:num>b</bcl:num>
              <bcl:text>the drug that was designated before April 1, 2013, as the reference drug comparator for the reference drug category;</bcl:text>
            </bcl:paragraph>
            <bcl:paragraph id="d2e814">
              <bcl:num>c</bcl:num>
              <bcl:text>the drug, in the reference drug category, that, in the opinion of the minister, will best serve the public interest if designated as the reference drug comparator for the reference drug category.</bcl:text>
            </bcl:paragraph>
          </bcl:subsection>
          <bcl:subsection id="d2e824">
            <bcl:num>5</bcl:num>
            <bcl:text>The minister must determine the daily therapeutic dose of the reference drug comparator, the daily therapeutic dose being</bcl:text>
            <bcl:paragraph id="d2e833">
              <bcl:num>a</bcl:num>
              <bcl:text>the typical dose that is prescribed, and</bcl:text>
            </bcl:paragraph>
            <bcl:paragraph id="d2e842">
              <bcl:num>b</bcl:num>
              <bcl:text>the number of doses that a beneficiary would typically receive each day.</bcl:text>
            </bcl:paragraph>
          </bcl:subsection>
          <bcl:subsection id="d2e851">
            <bcl:num>6</bcl:num>
            <bcl:text>The minister may change or cancel a determination or designation made under this section.</bcl:text>
          </bcl:subsection>
          <bcl:subsection id="d2e860">
            <bcl:num>7</bcl:num>
            <bcl:text>A change or cancellation under subsection (6) may be made at any time without notice to anyone or an opportunity to be heard.</bcl:text>
          </bcl:subsection>
          <bcl:subsection id="d2e869">
            <bcl:num>8</bcl:num>
            <bcl:text>The minister must publish on the website of the ministry of the minister a list of all of the following for each reference drug category:</bcl:text>
            <bcl:paragraph id="d2e879">
              <bcl:num>a</bcl:num>
              <bcl:text>the drugs that are included;</bcl:text>
            </bcl:paragraph>
            <bcl:paragraph id="d2e888">
              <bcl:num>b</bcl:num>
              <bcl:text>the drugs that have been designated as reference drugs;</bcl:text>
            </bcl:paragraph>
            <bcl:paragraph id="d2e897">
              <bcl:num>c</bcl:num>
              <bcl:text>the drug that has been designated as the reference drug comparator and the applicable daily therapeutic dose;</bcl:text>
            </bcl:paragraph>
            <bcl:paragraph id="d2e906">
              <bcl:num>d</bcl:num>
              <bcl:text>the maximum daily amount the minister may pay under the Act for a non-reference drug, as determined under section 9 <in:desc>[maximum payment for non-reference drugs]</in:desc>.</bcl:text>
            </bcl:paragraph>
          </bcl:subsection>
          <bcl:hnote>[am. B.C. Reg. 255/2015.]</bcl:hnote>
        </bcl:section>
        <bcl:section id="d2e919">
          <bcl:marginalnote>High cost drugs</bcl:marginalnote>
          <bcl:num>7</bcl:num>
          <bcl:subsection id="d2e927">
            <bcl:num>1</bcl:num>
            <bcl:text>The minister may designate a drug as a high cost drug if the minister determines that the maximum daily amount the minister may pay for the drug when averaged over a one-year period is equal to or greater than $40, having regard to the following factors:</bcl:text>
            <bcl:paragraph id="d2e936">
              <bcl:num>a</bcl:num>
              <bcl:text>the maximum amount the minister would otherwise pay, as determined under section 11 <in:desc>[prices for other drugs]</in:desc>, if the drug were not designated as a high cost drug;</bcl:text>
            </bcl:paragraph>
            <bcl:paragraph id="d2e948">
              <bcl:num>b</bcl:num>
              <bcl:text>the typical dose that is prescribed;</bcl:text>
            </bcl:paragraph>
            <bcl:paragraph id="d2e958">
              <bcl:num>c</bcl:num>
              <bcl:text>the number of doses that a beneficiary would typically receive each year.</bcl:text>
            </bcl:paragraph>
          </bcl:subsection>
          <bcl:subsection id="d2e967">
            <bcl:num>2</bcl:num>
            <bcl:text>The minister must publish on the website of the ministry of the minister a list of all high cost drugs.</bcl:text>
          </bcl:subsection>
        </bcl:section>
      </bcl:division>
      <bcl:division id="d2e977">
        <bcl:num>2</bcl:num>
        <bcl:text>Maximum Payment Amounts</bcl:text>
        <bcl:section id="d2e990">
          <bcl:marginalnote>Minister must not pay more than maximum amount</bcl:marginalnote>
          <bcl:num>8</bcl:num>
          <bcl:text>The minister must not make a payment under the Act for a drug in an amount that is greater than provided for in this Division.</bcl:text>
        </bcl:section>
        <bcl:section id="d2e1002">
          <bcl:marginalnote>Maximum payment for non-reference drugs</bcl:marginalnote>
          <bcl:num>9</bcl:num>
          <bcl:subsection id="d2e1010">
            <bcl:num>1</bcl:num>
            <bcl:text>The maximum amount the minister may pay for a non-reference drug that is not subject to the LCA program is the lesser of</bcl:text>
            <bcl:paragraph id="d2e1019">
              <bcl:num>a</bcl:num>
              <bcl:text>the sum of the manufacturer's list price for the drug and 8% of that price, and</bcl:text>
            </bcl:paragraph>
            <bcl:paragraph id="d2e1028">
              <bcl:num>b</bcl:num>
              <bcl:text>the maximum daily amount the minister may pay for the reference drug comparator for the reference drug category to which the non-reference drug belongs, as if the reference drug comparator were being dispensed at the daily therapeutic dose determined under section 6 (5) <in:desc>[reference drug program]</in:desc>.</bcl:text>
            </bcl:paragraph>
          </bcl:subsection>
          <bcl:subsection id="d2e1041">
            <bcl:num>2</bcl:num>
            <bcl:text>The maximum amount the minister may pay for a non-reference drug that is subject to the LCA program is the lesser of</bcl:text>
            <bcl:paragraph id="d2e1050">
              <bcl:num>a</bcl:num>
              <bcl:text>the amount determined under subsection (1), as if the non-reference drug were not subject to the LCA program, and</bcl:text>
            </bcl:paragraph>
            <bcl:paragraph id="d2e1059">
              <bcl:num>b</bcl:num>
              <bcl:text>either,</bcl:text>
              <bcl:subparagraph id="d2e1068">
                <bcl:num>i</bcl:num>
                <bcl:text>if there are no provisional drugs in the LCA category to which the non-reference drug belongs, the sum of the maximum accepted list price for the LCA category to which the drug belongs and 8% of that price, or</bcl:text>
              </bcl:subparagraph>
              <bcl:subparagraph id="d2e1077">
                <bcl:num>ii</bcl:num>
                <bcl:text>if there are provisional drugs in the LCA category to which the non-reference drug belongs, the maximum amount the minister may pay for a drug under section 11 (4) <in:desc>[prices for other drugs]</in:desc>.</bcl:text>
              </bcl:subparagraph>
            </bcl:paragraph>
          </bcl:subsection>
        </bcl:section>
        <bcl:section id="d2e1090">
          <bcl:marginalnote>Maximum payment for high cost drugs</bcl:marginalnote>
          <bcl:num>10</bcl:num>
          <bcl:subsection id="d2e1098">
            <bcl:num>1</bcl:num>
            <bcl:text>The maximum amount the minister may pay for a high cost drug that is not subject to the LCA program is the sum of the manufacturer's list price for the drug and 5% of that price.</bcl:text>
          </bcl:subsection>
          <bcl:subsection id="d2e1107">
            <bcl:num>2</bcl:num>
            <bcl:text>The maximum amount the minister may pay for a high cost drug that is subject to the LCA program is the lesser of</bcl:text>
            <bcl:paragraph id="d2e1116">
              <bcl:num>a</bcl:num>
              <bcl:text>the amount determined under subsection (1), as if the high cost drug were not subject to the LCA program, and</bcl:text>
            </bcl:paragraph>
            <bcl:paragraph id="d2e1126">
              <bcl:num>b</bcl:num>
              <bcl:text>the applicable amount from among the following:</bcl:text>
              <bcl:subparagraph id="d2e1135">
                <bcl:num>i</bcl:num>
                <bcl:text>if, in the LCA category to which the high cost drug belongs, there are only high cost drugs and none are provisional drugs, the sum of the maximum accepted list price for the LCA category to which the drug belongs and 5% of that price;</bcl:text>
              </bcl:subparagraph>
              <bcl:subparagraph id="d2e1144">
                <bcl:num>ii</bcl:num>
                <bcl:text>if, in the LCA category to which the high cost drug belongs, there are one or more drugs that are not high cost drugs but there are no provisional drugs, the sum of the maximum accepted list price for the LCA category to which the drug belongs and 8% of that price;</bcl:text>
              </bcl:subparagraph>
              <bcl:subparagraph id="d2e1153">
                <bcl:num>iii</bcl:num>
                <bcl:text>if, in the LCA category to which the high cost drug belongs, there are one or more provisional drugs, the maximum amount the minister may pay for a drug under section 11 (4) <in:desc>[prices for other drugs]</in:desc>.</bcl:text>
              </bcl:subparagraph>
            </bcl:paragraph>
          </bcl:subsection>
        </bcl:section>
        <bcl:section id="d2e1166">
          <bcl:marginalnote>Prices for other drugs</bcl:marginalnote>
          <bcl:num>11</bcl:num>
          <bcl:subsection id="d2e1174">
            <bcl:num>1</bcl:num>
            <bcl:text>This section applies to drugs other than non-reference drugs and high cost drugs.</bcl:text>
          </bcl:subsection>
          <bcl:subsection id="d2e1183">
            <bcl:num>2</bcl:num>
            <bcl:text>The maximum amount the minister may pay for a drug that is not subject to the LCA program is the sum of the manufacturer's list price for the drug and 8% of that price.</bcl:text>
          </bcl:subsection>
          <bcl:subsection id="d2e1192">
            <bcl:num>3</bcl:num>
            <bcl:text>The maximum amount the minister may pay for a drug that is subject to the LCA program and is in an LCA category having no provisional drugs is the lesser of</bcl:text>
            <bcl:paragraph id="d2e1202">
              <bcl:num>a</bcl:num>
              <bcl:text>the sum of the maximum accepted list price for the LCA category to which the drug belongs and 8% of that price, and</bcl:text>
            </bcl:paragraph>
            <bcl:paragraph id="d2e1211">
              <bcl:num>b</bcl:num>
              <bcl:text>the sum of the manufacturer's list price for the drug and 8% of that price.</bcl:text>
            </bcl:paragraph>
          </bcl:subsection>
          <bcl:subsection id="d2e1220">
            <bcl:num>4</bcl:num>
            <bcl:text>The maximum amount the minister may pay for a drug that is subject to the LCA program and is in an LCA category having one or more provisional drugs is the sum of the manufacturer's list price for the highest-priced provisional drug and</bcl:text>
            <bcl:paragraph id="d2e1229">
              <bcl:num>a</bcl:num>
              <bcl:text>8% of that price if the provisional drug is not a high cost drug, or</bcl:text>
            </bcl:paragraph>
            <bcl:paragraph id="d2e1238">
              <bcl:num>b</bcl:num>
              <bcl:text>5% of that price if the provisional drug is a high cost drug.</bcl:text>
            </bcl:paragraph>
          </bcl:subsection>
          <bcl:subsection id="d2e1247">
            <bcl:num>5</bcl:num>
            <bcl:text>Despite subsections (2) to (4) of this section, if an agreement under section 20 (2) <in:desc>[price regulation]</in:desc> of the Act includes a term respecting the price of a drug, the maximum amount the minister may pay for the drug is the agreed price.</bcl:text>
          </bcl:subsection>
        </bcl:section>
        <bcl:section id="d2e1260">
          <bcl:marginalnote>Price if unanticipated drug shortage</bcl:marginalnote>
          <bcl:num>12</bcl:num>
          <bcl:subsection id="d2e1268">
            <bcl:num>1</bcl:num>
            <bcl:text>This section applies to</bcl:text>
            <bcl:paragraph id="d2e1277">
              <bcl:num>a</bcl:num>
              <bcl:text>a brand drug within an LCA category having an insufficient supply of drugs as described in section 16 (1) <in:desc>[temporary listing of drugs]</in:desc>, and</bcl:text>
            </bcl:paragraph>
            <bcl:paragraph id="d2e1289">
              <bcl:num>b</bcl:num>
              <bcl:text>a drug that is temporarily listed under section 16 (2).</bcl:text>
            </bcl:paragraph>
          </bcl:subsection>
          <bcl:subsection id="d2e1299">
            <bcl:num>2</bcl:num>
            <bcl:text>If section 16 (1) applies, despite sections 9 <in:desc>[maximum payment for non-reference drugs]</in:desc> to 11 <in:desc>[prices for other drugs]</in:desc>, the maximum amount the minister may pay for a drug referred to in subsection (1) of this section during the period of unanticipated shortage is as follows:</bcl:text>
            <bcl:paragraph id="d2e1314">
              <bcl:num>a</bcl:num>
              <bcl:text>if the drug is a non-reference drug, the lesser of</bcl:text>
              <bcl:subparagraph id="d2e1323">
                <bcl:num>i</bcl:num>
                <bcl:text>the sum of the manufacturer's list price for the drug and 8% of that price, and</bcl:text>
              </bcl:subparagraph>
              <bcl:subparagraph id="d2e1332">
                <bcl:num>ii</bcl:num>
                <bcl:text>the maximum daily amount the minister may pay for the reference drug comparator for the reference drug category to which the non-reference drug belongs, as if the reference drug comparator were being dispensed at the daily therapeutic dose determined under section 6 (5) <in:desc>[reference drug program]</in:desc>;</bcl:text>
              </bcl:subparagraph>
            </bcl:paragraph>
            <bcl:paragraph id="d2e1344">
              <bcl:num>b</bcl:num>
              <bcl:text>if the drug is a high cost drug, the sum of the manufacturer's list price for the drug and 5% of that price;</bcl:text>
            </bcl:paragraph>
            <bcl:paragraph id="d2e1353">
              <bcl:num>c</bcl:num>
              <bcl:text>in any other case, the sum of the manufacturer's list price for the drug and 8% of that price.</bcl:text>
            </bcl:paragraph>
          </bcl:subsection>
        </bcl:section>
        <bcl:section id="d2e1363">
          <bcl:marginalnote>Price if inter-jurisdictional agreement applies</bcl:marginalnote>
          <bcl:num>13</bcl:num>
          <bcl:text>If the government of British Columbia is a party, with the government of one or more other jurisdictions, to an agreement, a memorandum of understanding or another similar arrangement that is designed to provide for a supply of drugs at a price that is lower than the maximum amount the minister would otherwise pay under this Division,</bcl:text>
          <bcl:paragraph id="d2e1374">
            <bcl:num>a</bcl:num>
            <bcl:text>sections 9 <in:desc>[maximum payment for non-reference drugs]</in:desc> to 12 <in:desc>[price if unanticipated drug shortage]</in:desc> do not apply, and</bcl:text>
          </bcl:paragraph>
          <bcl:paragraph id="d2e1389">
            <bcl:num>b</bcl:num>
            <bcl:text>the maximum amount the minister may pay for a drug affected by the agreement, memorandum of understanding or arrangement is the amount resulting from the implementation of the agreement, memorandum of understanding or arrangement.</bcl:text>
          </bcl:paragraph>
        </bcl:section>
      </bcl:division>
    </bcl:part>
    <bcl:part id="d2e1400">
      <bcl:num>3</bcl:num>
      <bcl:text>Listing Drugs</bcl:text>
      <bcl:section id="d2e1409">
        <bcl:marginalnote>Designation of provisional drugs</bcl:marginalnote>
        <bcl:num>14</bcl:num>
        <bcl:subsection id="d2e1417">
          <bcl:num>1</bcl:num>
          <bcl:text>The minister may designate a generic drug as a provisional drug if any of the following circumstances apply:</bcl:text>
          <bcl:paragraph id="d2e1426">
            <bcl:num>a</bcl:num>
            <bcl:text>the minister is of the opinion that</bcl:text>
            <bcl:subparagraph id="d2e1435">
              <bcl:num>i</bcl:num>
              <bcl:text>there will be an insufficient supply of drugs within an LCA category, and</bcl:text>
            </bcl:subparagraph>
            <bcl:subparagraph id="d2e1445">
              <bcl:num>ii</bcl:num>
              <bcl:text>listing the drug on a formulary is necessary to ensure a sufficient supply of drugs within the LCA category to which the drug is or would be assigned;</bcl:text>
            </bcl:subparagraph>
          </bcl:paragraph>
          <bcl:paragraph id="d2e1454">
            <bcl:num>b</bcl:num>
            <bcl:text>the drug could otherwise not be listed on a formulary under section 15 (2) (a) <in:desc>[minister not to list certain generic drugs]</in:desc>, but an agreement under section 20 (2) <in:desc>[price regulation]</in:desc> of the Act includes a term respecting the price of the drug;</bcl:text>
          </bcl:paragraph>
          <bcl:paragraph id="d2e1469">
            <bcl:num>c</bcl:num>
            <bcl:text>the minister is of the opinion that listing the drug on a formulary is in the public interest.</bcl:text>
          </bcl:paragraph>
        </bcl:subsection>
        <bcl:subsection id="d0e1701">
          <bcl:num>1.1</bcl:num>
          <bcl:text>A generic drug's designation as a provisional drug is cancelled as follows:</bcl:text>
          <bcl:paragraph id="d0e1709">
            <bcl:num>a</bcl:num>
            <bcl:text>Repealed. [B.C. Reg. 22/2019, s. 7.]</bcl:text>
          </bcl:paragraph>
          <bcl:paragraph id="d0e1718">
            <bcl:num>b</bcl:num>
            <bcl:text>if the circumstances referred to in subsection (1) (a), (b) and (c) no longer apply, the minister may, at any time, cancel a designation made under this section in respect of any generic drug.</bcl:text>
          </bcl:paragraph>
        </bcl:subsection>
        <bcl:subsection id="d2e1478">
          <bcl:num>2</bcl:num>
          <bcl:text>The minister may cancel a designation made under this section without notice to anyone or an opportunity to be heard.</bcl:text>
        </bcl:subsection>
        <bcl:subsection id="d2e1487">
          <bcl:num>3</bcl:num>
          <bcl:text>Repealed. [B.C. Reg. 22/2019, s. 7.]</bcl:text>
        </bcl:subsection>
        <bcl:hnote>[am. B.C. Regs. 266/2016, Sch. 2, s. 3; 22/2019, s. 7.]</bcl:hnote>
      </bcl:section>
      <bcl:section id="d2e1500">
        <bcl:marginalnote>Minister not to list certain generic drugs</bcl:marginalnote>
        <bcl:num>15</bcl:num>
        <bcl:subsection id="d2e1508">
          <bcl:num>1</bcl:num>
          <bcl:text>This section applies to a generic drug that is or would be assigned to an LCA category, but does not apply to a generic drug that is</bcl:text>
          <bcl:paragraph id="d2e1517">
            <bcl:num>a</bcl:num>
            <bcl:text>a provisional drug, or</bcl:text>
          </bcl:paragraph>
          <bcl:paragraph id="d2e1526">
            <bcl:num>b</bcl:num>
            <bcl:text>the subject of a term of an agreement, a memorandum of understanding or another arrangement under section 13 <in:desc>[price if inter-jurisdictional agreement applies]</in:desc>.</bcl:text>
          </bcl:paragraph>
        </bcl:subsection>
        <bcl:subsection id="d2e1539">
          <bcl:num>2</bcl:num>
          <bcl:text>The minister must refuse to list on a formulary a drug described in subsection (1), or must cancel the listing on a formulary of a drug described in subsection (1), if either of the following circumstances applies:</bcl:text>
          <bcl:paragraph id="d2e1548">
            <bcl:num>a</bcl:num>
            <bcl:text>the manufacturer's list price for the drug is higher than the maximum accepted list price for the LCA category to which the drug is or would be assigned;</bcl:text>
          </bcl:paragraph>
          <bcl:paragraph id="d2e1557">
            <bcl:num>b</bcl:num>
            <bcl:text>the manufacturer of the drug fails to supply information satisfactory to the minister respecting the drug within the time required by the minister.</bcl:text>
          </bcl:paragraph>
        </bcl:subsection>
        <bcl:subsection id="d2e1566">
          <bcl:num>3</bcl:num>
          <bcl:text>Repealed. [B.C. Reg. 22/2019, s. 7.]</bcl:text>
        </bcl:subsection>
        <bcl:hnote>[am. B.C. Regs. 266/2016, Sch. 2, s. 4; 22/2019, s. 7.]</bcl:hnote>
      </bcl:section>
      <bcl:section id="d2e1579">
        <bcl:marginalnote>Temporary listing of drugs</bcl:marginalnote>
        <bcl:num>16</bcl:num>
        <bcl:subsection id="d2e1587">
          <bcl:num>1</bcl:num>
          <bcl:text>This section applies if the minister</bcl:text>
          <bcl:paragraph id="d2e1596">
            <bcl:num>a</bcl:num>
            <bcl:text>is of the opinion that there is, or there is about to be, an insufficient supply of drugs within an LCA category, and</bcl:text>
          </bcl:paragraph>
          <bcl:paragraph id="d2e1605">
            <bcl:num>b</bcl:num>
            <bcl:text>could not reasonably have anticipated the insufficient supply.</bcl:text>
          </bcl:paragraph>
        </bcl:subsection>
        <bcl:subsection id="d2e1615">
          <bcl:num>2</bcl:num>
          <bcl:text>Despite any other provision of this Part, the minister may list on a formulary, for the purpose of ensuring a sufficient supply of drugs within an LCA category, a drug that could not otherwise be listed.</bcl:text>
        </bcl:subsection>
        <bcl:subsection id="d2e1624">
          <bcl:num>3</bcl:num>
          <bcl:text>The minister must cancel the listing of the drug when the minister is of the opinion that the period of unanticipated shortage has ended.</bcl:text>
        </bcl:subsection>
      </bcl:section>
    </bcl:part>
    <bcl:part id="d2e1634">
      <bcl:num>4</bcl:num>
      <bcl:section id="d2e1643">
        <bcl:marginalnote>Repealed</bcl:marginalnote>
        <bcl:num>17</bcl:num>
        <bcl:text>Repealed. [B.C. Reg. 266/2016, Sch. 2, s. 5.]</bcl:text>
      </bcl:section>
    </bcl:part>
    <bcl:schedule id="d0e1795">
      <bcl:scheduletitle>Schedule</bcl:scheduletitle>
      <bcl:centertext>[am. B.C. Reg. 159/2013.]</bcl:centertext>
      <bcl:lefttext>
        <in:em>The Schedule is exempt from publication and can be viewed at the following location:</in:em>
      </bcl:lefttext>
      <bcl:indent1>Pharmaceutical Services Division<in:br/> Ministry of Health<in:br/> 3rd floor, 1515 Blanshard Street<in:br/> Victoria, B.C. V8W 3C8</bcl:indent1>
      <bcl:indent1>Website: <in:a href="http://www.health.gov.bc.ca/pharmacare/publications.html">www.health.gov.bc.ca/pharmacare/publications.html</in:a></bcl:indent1>
    </bcl:schedule>
    <reg:provisionsnote>[Provisions relevant to the enactment of this regulation: <bcl:link resource="leg" xlink:href="/legislation/12022_01" xlink:type="locator"><in:doc>Pharmaceutical Services Act</in:doc></bcl:link>, S.B.C. 2012, c. 22, ss. 62 (1) and (2) and 65 (3) and (5)]</reg:provisionsnote>
  </reg:content>
</reg:regulation>